Health Sector Headlines: WHO, Measles Outbreaks, and Drug Developments

The U.S. continues its involvement with WHO discussions on flu vaccines despite planned exit. Health Secretary Kennedy prioritizes ending a Texas measles outbreak. The FDA updates testosterone product labels, while Eli Lilly warns against unapproved weight-loss drugs. Various pharmaceutical developments are highlighted, such as Sun Pharma's new drug plans.

Despite the U.S.'s planned exit from the World Health Organization, American health agencies took part in a critical meeting to discuss the composition of forthcoming flu vaccines. This decision underscores the ongoing collaboration on urgent global health concerns despite political decisions by former President Trump to initiate withdrawal.

U.S. Health Secretary Robert F. Kennedy Jr. faced both applause and scrutiny after prioritizing rapid actions against a severe measles outbreak in Texas, with the tragic loss of a child's life. The HHS is stepping up its response by dispatching vaccines, reinforced by Kennedy's historical skepticism about immunizations.

The U.S. FDA has unveiled new labeling requirements for testosterone therapies, emphasizing cardiovascular risks. Concurrently, Eli Lilly has embarked on a direct appeal to the public, urging skepticism towards unapproved weight-loss products that mimic its own, illustrating heightened competition in an expanding pharmaceutical market.

(With inputs from agencies.)